Literature DB >> 27989898

Inflammation elevated IL-33 originating from the lung mediates inflammation in acute lung injury.

Shi-Hui Lin1, Juan Fu1, Chuan-Jiang Wang1, Feng Gao1, Xuan-Yun Feng1, Qiong Liu1, Ju Cao2, Fang Xu3.   

Abstract

Excessive inflammatory reactions occur with acute respiratory distress syndrome (ARDS), however, the underlying mechanisms of ARDS remain incompletely understood. Here we investigated whether interleukin (IL)-33 was elevated in ARDS patients. Serum samples were obtained from 14 ARDS patients and 24 control healthy volunteers. ELISA was used to measure the concentrations of IL-33. Besides, we established pulmonary ARDS and extrapulmonary ARDS models in mice, and serum and lung tissue samples were collected for analyses. The results showed that serum IL-33 concentrations were significantly higher in pulmonary ARDS patients compared to controls. Also, the levels of IFN-γ and IL-2 were positively correlated with IL-33 levels. We also showed that there were increased IL-33 levels in both the serum and lungs in the pulmonary ARDS model. This was not the case, however, in the extrapulmonary ARDS model. Pulmonary inflammation and injury in the pulmonary ARDS model was reduced with IL-33 neutralizing antibody treatment.
Copyright © 2016. Published by Elsevier Inc.

Entities:  

Keywords:  Acute respiratory distress syndrome; Cytokine; Inflammation; Interleukin-33

Year:  2016        PMID: 27989898     DOI: 10.1016/j.clim.2016.10.014

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  9 in total

1.  The role of IL-1 family of cytokines and receptors in pathogenesis of COVID-19.

Authors:  Shima Makaremi; Ali Asgarzadeh; Hamed Kianfar; Alireza Mohammadnia; Vahid Asghariazar; Elham Safarzadeh
Journal:  Inflamm Res       Date:  2022-06-25       Impact factor: 6.986

Review 2.  Stem Cell-based therapies for COVID-19-related acute respiratory distress syndrome.

Authors:  Hoi Wa Ngai; Dae Hong Kim; Mohamed Hammad; Margarita Gutova; Karen Aboody; Christopher D Cox
Journal:  J Cell Mol Med       Date:  2022-04-14       Impact factor: 5.295

Review 3.  Scrub Typhus Pathogenesis: Innate Immune Response and Lung Injury During Orientia tsutsugamushi Infection.

Authors:  Brandon Trent; James Fisher; Lynn Soong
Journal:  Front Microbiol       Date:  2019-09-06       Impact factor: 5.640

4.  IL-33 and its increased serum levels as an alarmin for imminent pulmonary complications in polytraumatized patients.

Authors:  Gabriel Halát; Thomas Haider; Michel Dedeyan; Thomas Heinz; Stefan Hajdu; Lukas L Negrin
Journal:  World J Emerg Surg       Date:  2019-07-19       Impact factor: 5.469

5.  Potential therapeutic effects of interleukin-35 on the differentiation of naïve T cells into Helios+Foxp3+ Tregs in clinical and experimental acute respiratory distress syndrome.

Authors:  Chuanjiang Wang; Ke Xie; Kefeng Li; Shihui Lin; Fang Xu
Journal:  Mol Immunol       Date:  2021-01-16       Impact factor: 4.407

6.  IL-35 interferes with splenic T cells in a clinical and experimental model of acute respiratory distress syndrome.

Authors:  Chuan-Jiang Wang; Mu Zhang; Hua Wu; Shi-Hui Lin; Fang Xu
Journal:  Int Immunopharmacol       Date:  2018-12-22       Impact factor: 4.932

7.  Cyclic stretch induced IL-33 production through HMGB1/TLR-4 signaling pathway in murine respiratory epithelial cells.

Authors:  Jing Chang; Yuefeng Xia; Karla Wasserloos; Meihong Deng; Kory J Blose; David A Vorp; Heth R Turnquist; Timothy R Billiar; Bruce A Pitt; Ma-Zhong Zhang; Li-Ming Zhang
Journal:  PLoS One       Date:  2017-09-12       Impact factor: 3.240

Review 8.  Coronavirus disease 2019 (COVID-19): cytokine storms, hyper-inflammatory phenotypes, and acute respiratory distress syndrome.

Authors:  Shi-Hui Lin; Yi-Si Zhao; Dai-Xing Zhou; Fa-Chun Zhou; Fang Xu
Journal:  Genes Dis       Date:  2020-06-29

Review 9.  Regulatory T Cells and Acute Lung Injury: Cytokines, Uncontrolled Inflammation, and Therapeutic Implications.

Authors:  Shihui Lin; Hua Wu; Chuanjiang Wang; Zhibo Xiao; Fang Xu
Journal:  Front Immunol       Date:  2018-07-09       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.